Hepatitis b cure latest news

Here are the latest updates on hepatitis B cure:

Vaccines:

• The World Health Organization (WHO) recommends that all newborns receive the first dose of hepatitis B vaccine within 24 hours of birth.
• The Centers for Disease Control and Prevention (CDC) recommends that all infants receive the first dose of hepatitis B vaccine at birth, followed by two additional doses at 1-2 months and 6-18 months of age.

Treatment:

• The standard treatment for chronic hepatitis B (CHB) is antiviral therapy, which can help suppress the virus and prevent liver damage.
• The most commonly used antiviral medications for CHB are:
  • Nucleoside/nucleotide analogues (e.g., lamivudine, adefovir, tenofovir)
  • Pegylated interferon
  • Combination therapy (e.g., tenofovir + lamivudine)
• The goal of treatment is to achieve undetectable levels of HBV DNA in the blood, which can reduce the risk of liver damage and liver cancer.

New Developments:

• In 2020, the FDA approved the first oral antiviral medication for CHB, tenofovir alafenamide (TAF), which has been shown to be more effective and better tolerated than previous treatments.
• Researchers are exploring new treatments, including:
  • Immunotherapy: using the body's immune system to fight the virus
  • Gene therapy: using genetic material to correct mutations that contribute to CHB
  • Stem cell therapy: using stem cells to regenerate liver tissue and improve liver function

Cure:

• While there is no cure for hepatitis B, antiviral therapy can help manage the disease and reduce the risk of complications.
• The WHO estimates that 90% of people with CHB can achieve a sustained virological response (SVR) with antiviral therapy, which means that the virus is undetectable in the blood for at least 6 months after treatment is stopped.
• Researchers are working to develop a cure for CHB, but it is a complex and challenging process.

Recent Studies:

• A 2020 study published in the Journal of Hepatology found that a combination of tenofovir and lamivudine was effective in achieving SVR in 90% of patients with CHB.
• A 2020 study published in the New England Journal of Medicine found that a new oral antiviral medication, brincidofovir, was effective in reducing HBV DNA levels in patients with CHB.

Current Research:

• Researchers are actively exploring new treatments and therapies for CHB, including:
  • Investigational antiviral medications, such as GS-9620 and GS-6207
  • Immunotherapy approaches, such as checkpoint inhibitors and adoptive T-cell therapy
  • Gene therapy approaches, such as CRISPR-Cas9 gene editing

Please note that the information provided is subject to change and may not reflect the most up-to-date information. It is always best to consult with a healthcare professional for personalized advice and treatment.